Array Biopharma (ARRY) Adds to Gains; Shares Up 70%

September 26, 2016 2:03 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Array Biopharma (NASDAQ: ARRY) is pushing to the highs of the session. Shares are now up 70% after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic melanoma.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Add Your Comment